Научно-практическая ревматология
Т. 55, Вып. 5, С. 536-548
Аннотация:
The need for further improvement of treatments for Takayasu's arteritis (TA), the progress in understanding the mechanisms of the disease, and the introduction of biological agents (BA) in rheumatology practice have created preconditions for developing a new TA pharmacotherapy using BA associated with interleukin 6 (IL-6) inhibition. The authors describe their two own cases of tocilizumab (TCZ) use for complicated TA. They analyze the results of TCZ treatment by the data of preliminary trials in 115 patients with TA, which have been published in 30 literature sources, as well as the results of Phase III double-blind, randomized placebo-controlled trials (RPCTs) of the safety and efficacy of TCZ in 18 patients with refractory TA. In one case with a long history of complicated TA, the control of TA activity and the reduction in the dose of glucocorticoids due to TCZ use contributed to the favorable course of pregnancy and labor. In the other case with the onset of TA and focal pulmonary
Бекетова Т. В. Татьяна Валентиновна 0001-
Насонов Е. Л. Евгений Львович 1948-
Beketova T. V. Tat`yana Valentinovna 0001-
Nasonov E. L. Evgenij L`vovich 1948-
Innovative treatments for takayasu's arteritis: A focus on interleukin-6 inhibitors. The authors' experience with tocilizumab and a review of literature
Innovative treatments for takayasu's arteritis: A focus on interleukin-6 inhibitors. The authors' experience with tocilizumab and a review of...
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 55, Вып. 5 С. 536-548
2017
Обзор
Interleukin 6 Takayasu's arteritis Tocilizumab
The need for further improvement of treatments for Takayasu's arteritis (TA), the progress in understanding the mechanisms of the disease, and the introduction of biological agents (BA) in rheumatology practice have created preconditions for developing a new TA pharmacotherapy using BA associated with interleukin 6 (IL-6) inhibition. The authors describe their two own cases of tocilizumab (TCZ) use for complicated TA. They analyze the results of TCZ treatment by the data of preliminary trials in 115 patients with TA, which have been published in 30 literature sources, as well as the results of Phase III double-blind, randomized placebo-controlled trials (RPCTs) of the safety and efficacy of TCZ in 18 patients with refractory TA. In one case with a long history of complicated TA, the control of TA activity and the reduction in the dose of glucocorticoids due to TCZ use contributed to the favorable course of pregnancy and labor. In the other case with the onset of TA and focal pulmonary